Lungs exposed to 1 hour warm ischemia without heparin before harvesting might be suitable candidates for transplantation by Annika Liersch-Nordqvist et al.
RESEARCH ARTICLE Open Access
Lungs exposed to 1 hour warm ischemia
without heparin before harvesting might
be suitable candidates for transplantation
Annika Liersch-Nordqvist1, Richard Ingemansson2, Leif Pierre2, Joanna Hlebowicz3 and Sandra Lindstedt2*
Abstract
Background: The limiting factor for lung transplantation is the lack of donor organs. The usage of lungs from
donation after cardiac death (DCD) would dramatically increase donor availability. In the present paper we wanted
to investigate lungs exposed to 1 h of warm ischemia without heparin followed by flush-perfusion and cold storage
compared to lungs harvested from heart beating donors (HBD) using standard harvesting technique.
Methods: Twelve Swedish domestic pigs were randomized into two groups. Six pigs (DCD group) underwent
ventricular fibrillation and were then left untouched for 1 h after declaration of death. They did not receive
heparin. The lungs were then harvested and flush-perfused with Perfadex® solution and the organs were stored
at 8 °C for 4 h. Six pigs (HBD group) received heparin and the lungs were harvested and flush-perfused with
Perfadex® solution and the organs were stored at 8 °C for 4 h. Lung function was evaluated, using ex vivo lung
perfusion (EVLP), with blood gases at different oxygen levels, pulmonary vascular resistance (PVR), lung weight,
and macroscopic appearance.
Results: At FiO2 1.0, the PaO2 in the DCD group was 51.7 ± 2.0 kPa and in the HBD group 68.6 ± 2.4 kPa (p < 0.01).
Significantly lower PVR levels were measured in the DCD group (372 ± 31 dyne x s/cm5) compared to the HBD
group (655 ± 45 dyne x s/cm5) (p < 0.001). There was no significant difference between groups in weight, compliance
or signs of pulmonary thrombosis or embolization.
Conclusions: It seems as if DCD lungs exposed to 1 h of warm ischemia before 4 h of cold storage has satisfying
oxygenation capacity, low PVR, normal weight and no signs of thrombosis or embolization. According to our study it
seems as lungs exposed to 1 h warm ischemia without heparin might be good candidates for transplantation.
Keywords: Lung transplantation, Donation after cardiac death, Ex vivo lung perfusion, Experimental animal study, Heart
beating donor
Background
The shortage of suitable organ donors is still a limiting
factor for lung transplantation. Only about 20 % of suit-
able donor lungs are being transplanted [1, 2]. This
leaves a growing number of patients with end-stage pul-
monary disease remaining indefinitely on the waiting list
for lung transplantation. In recent years, the use of
donation after cardiac death (DCD) donors for lung
transplantation has grown in interest and is entering
clinical practice [3–5]. To be able to evaluate the donor
lungs from DCD, the ex vivo lung evaluation (EVLP)
method was developed and established by Steen and col-
leagues at our clinic at the Skane University hospital in
Sweden. The EVLP method is today mainly used for
lung evaluation in donor lungs from heart beating
donors (HBD), where the lungs have initially been
rejected prior to eventual clinical lung transplantation at
many cardiothoracic clinics all over the world [6–12].
The increasing interest in DCD to increase donor
organs has led to extensive research in the field of EVLP
and the ideal preservation method. There are reports
demonstrating that a time frame of 60 min of warm
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ischemia does not seem to compromise the pulmonary
graft [13–15]. In these publications all animals received
heparin before being exposed to the warm ischemia.
In clinical lung transplantation today the donor
receives intravenous heparin prior to lung harvesting to
avoid lung thrombosis in the lung grafts. In DCD lungs,
heparin would need to be recirculated. It is currently
being debated whether it is ethically and legal permis-
sible to give a patient heparin after death has been
declared but before permission for donation has been
received, particularly given the cardiac compressions
required to circulate heparin. The avoidance of heparin
would help overcome this ethical challenge.
In the present study we investigate the use of heparin
infusion prior to lung harvesting using standard clinical
routine in a HBD setting vs no heparin in a DCD setting
with 1 h warm ischemia before harvesting. Both groups
of lungs were flush-perfused with Perfadex® solution and
stored for 4 h at 8 °C before being evaluated in the EVLP
system. Our intensions were to investigate if DCD lungs
without heparin is good enough to transplant regarding
blood gases, weight, compliance, thromboembolism and




Twelve Swedish landrace pigs were fasted overnight
with free access to water. The experimental protocol
for this study was approved by the Ethics Committee
for Animal Research, Lund University, Sweden, Dnr M
172-11. All animals received care according to the
European Convention of the Protection of Vertebrate
Animals used for Experimental and Other Scientific
Purposes, the National Society for Medical Research’s
Principles of Laboratory Animal Care, and the Institute
of Laboratory Animal Research’s Guide for the Care
and Use of Laboratory Animals. The experiments de-
scribed in the manuscript was a part of a larger project
setup with many different experimental groups.
The pigs were randomly assigned into 2 groups: the
HBD and the DCD group, each group consisting of 6
pigs. Premedication was performed with an intramuscu-
lar injection of Xylazine (Rompun® vet. 20 mg/ml; Bayer
AG, Leverkusen, Germany; 2 mg/kg) mixed with keta-
mine (Ketaminol® vet. 100 mg/ml; Farmaceutici Gellini
S.p.A., Aprilia, Italy; 20 mg/kg) in their stables, and a
peripheral iv access was established in the earlobe. The
pig was then transferred to the laboratory and placed in
supine position on the operating table. Oral intubation
was performed using a 7.5 size endotracheal tube after
anesthesia induction with sodium thiopental (Pentothal;
Abbott Laboratories, North Chicago, Illinois, USA) and
pancuronium bromide (Pavulon; N.V. Organon, Oss, the
Netherlands). Anesthesia was maintained with a ketamine
(Ketaminol® vet), midazolam (Midazolam Panpharma®,
Oslo, Norway), and fentanyl (Leptanal®, Lilly, France)
infusion. Fluid loss was compensated for by continuous
infusion of Ringer’s Acetate. Mechanical ventilation was
established with a Siemens-Elema ventilator (Servo
Ventilator 300, Siemens, Solna, Sweden) with an inspired
oxygen fraction (FiO2) of 0.5, a frequency of 15 breaths/
min, a minute ventilation of 6 l/min, and a positive end-
exspiratory pressure (PEEP) of 5 cmH2O.
Experimental timeline
The experimental timeline is demonstrated in Fig. 1.
Preservation of HBD Lungs
A median sternotomy was performed. Heparin sodium
(Heparin LEO; 400 IE/kg, LEO Pharma AB, Malmö,
Sweden,) was given intravenously. The pulmonary artery
was cannulated via the right ventricle with a 28 F can-
nula secured with a purse string suture placed in the
outflow tract of the pulmonary artery. A clamp was put
on the superior vena cava, and another clamp was put
on the inferior vena cava. A clamp was then put on the
ascending aorta. The left atrium and inferior vena cava
was opened. Ice slush was put in the right and left pleura
for cooling of the lungs. The lungs were perfused ante-
gradely with 4 L of cold Perfadex® solution with added
isotonic trometamol 1.0 ml (Addex-THAM 3.3 mmol/
ml; Fresenius Kabi AB Uppsala, Sweden), calcium chlor-
ide 2 ml (0.45 mmol/ml) and nitro-glycerine 3 ml
(5 mg/ml; BMM Pharma AB, Stockholm, Sweden) dis-
tributed at low perfusion pressure (<20 mmHg). The
cannula was removed from the pulmonary artery. The
lungs were harvested en bloc in a standard fashion. After
harvesting, the lungs were put on a scales and the lung
weight was noted. During retrieval, a segment (~8 cm)
of the descending aorta was also excised. The lungs were
immersed in cold Perfadex® solution with the aortic seg-
ment and put in cold storage at 8 °C for 4 h.
Preservation of DCD lungs
A median sternotomy was performed. Ventricular fibril-
lation was induced electrically. The tracheal tube was
disconnected from the ventilator when circulatory arrest
was confirmed and left open to air. After one hour after
the declaration of death the median sternotomy was
opened. The pulmonary artery was cannulated via the
right ventricle with a 28 F cannula secured with a purse
string suture placed in the outflow tract of the pulmon-
ary artery. A clamp was put on the superior vena cava,
and another clamp was put on the inferior vena cava. A
clamp was put on the ascending aorta. The left atrium
and inferior vena cava was opened.
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The lungs were perfused antegradely with 4 L of cold
Perfadex® solution with added isotonic trometamol 1.0 ml
(Addex-THAM 3.3 mmol/ml; Fresenius Kabi AB Uppsala,
Sweden), calcium chloride 2 ml (0.45 mmol/ml) and
nitro-glycerine 3 ml (5 mg/ml; BMM Pharma AB,
Stockholm, Sweden) distributed at low perfusion pressure
(< 20 mmHg).
The cannula was removed from the pulmonary artery.
The lungs were harvested en bloc in a standard fashion.
After harvesting, the lungs were put on a scale and the
lung weight was noted. During the retrieval, a segment
(~8 cm) of the descending aorta was also excised. The
lungs were immersed in cold Perfadex® solution with the
aortic segment and put in cold storage at 8 °C for 4 h.
Ex vivo lung perfusion
Ex vivo lung perfusion (EVLP) was performed using
the extracorporeal perfusion circuit by Medtronics
(Medtronic AB, Kerkrade, the Netherlands; Ex Vivo
Lung Evaluation Set).
The system was primed with albumin (500 ml, 50 g/l
and 200 ml 200 g/l; Albumin Baxter, Baxter Medical,
Kista, Sweden, and 2 units of autologous blood, earlier
withdrawn from each donor. Imipenem (0.5 g; Tienam,
Merck Sharp & Dohme, Sollentuna, Sweden), insulin
(20 IU; Actrapid; Novo Nordisk, Bagsvaerd, Denmark),
and heparin (10,000 IU; Leo Pharma, Malmö, Sweden)
were added, and isotonic trometamol (Addex-Tham,
Kabi, Sweden) was used to buffer the mixed solution to
a temperature adjusted pH of 7.4. Gas was supplied to
the membrane oxygenator; first oxygen and CO2 during
the reconditioning phase, and then 93 % nitrogen and
7 % CO2 during the testing phase, creating a normal
venous blood gas in the perfusate to the pulmonary
artery (i.e., the oxygenator is used to deoxygenate the
perfusate). Before the perfusion was started, the pulmon-
ary artery was extended by a segment of the descending
aorta to make cannulation easier. The pulmonary artery
cannula was then connected to the corresponding tube
of the extracorporeal circuit, the air was removed, and
the shunt of the circuit was clamped. An endotracheal
tube was secured in the trachea with a cotton band and
connected to the ventilator. The remnant of the left
atrium was left open, prohibiting pulmonary outflow
obstruction, and maintaining a constant left atrium pres-
sure around 0 mmHg.
A low-flow perfusion at 25 °C was initiated through the
lungs. The lungs were gradually warmed by increasing the
temperature of the perfusate. When the temperature
reached 32 °C, ventilation was started with a FiO2 of 0.5
and a minute volume of 1 L/min, and no positive end-
expiratory pressure (PEEP). The pump flow was gradually
increased, never allowing the pulmonary arterial pressure
to exceed 20 mmHg. With the temperature increase of
each 1 °C, ventilation was augmented with a correspond-
ing 1 L minute volume. After 20–30 min, normothermia
was reached and positive end-expiratory pressure was
added to fully expand the lungs and eliminate atelectasis.
Blood gases were analyzed under full ventilation at differ-
ent inspired oxygen fraction levels. Pulmonary vascular
resistance (PVR) was calculated using the formula PVR
(dyne*sec/cm5) = (80 * (Mean Pulmonary Artery Pressure
(PAP) – (Pulmonary Cap Wedge Press (PCW) e.g.Left
Atrial Pressure)) / Cardiac Output (C.O) e.g. Pulmonary
Artery Flow).
The lungs were then disconnected from the EVLP. A
deflation test was performed for a final evaluation of the
lungs by disconnecting the lungs from the ventilator at
the end of inspiration. The lungs were put onto a scale
and weighed. The pulmonary arterial branches were
macroscopically studied for thrombotic material by
opening the arteries as far distally as possible.
Calculations and statistics
Descriptive statistics, in the form of the number of ex-
perimental animals, mean, and the standard error on the
Fig. 1 The figure shows a timeline of the experimental setup for the two groups: Heart Beating Donor (HBD) and Donation after Cardiac Death
(DCD). The time for each procedural step is given as mean ± SEM. Ex Vivo Lung Perfusion is mentioned as EVLP in the timeline
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mean (SEM) for the different parameters were analyzed.
The descriptive results are presented for the different
parameters divided into the different groups (HBD, DCD).
Statistically significant difference between the different
groups was tested by a non-parametric Kruskal-Wallis-
test. Adjustments of the p-value were made according to
the Bonferroni correction. All statistical analysis was per-
formed, using SPSS version 20. Significance was defined




Animal weights in the groups were as follows: 60.2 ±
0.8 kg in the HBD group and 61.2 ± 1.4 kg in the DCD
group.
Pre-operative arterial oxygen partial pressure (PaO2) at
an FiO2 of 0.5 were in the HBD group 30.9 ± 0.7 kPa
and in the DCD group 29.1 ± 0.9 kPa. (n.s).
Pre-operative arterial carbondioxide partial pressure
(PaCO2) at an FiO2 of 0.5 were in the HBD group 6.5 ±
0.1 kPa and in the DCD group 6.0 ± 0.2 kPa (n.s.).
The EVLP time was 80 ± 9.7 min in the HBD group,
56 ± 3.3 min for the DCD group.
No anatomical anomalies, signs of infection, or malig-
nancy were found in any of the animals at autopsy.
Pulmonary gas function
Arterial and venous blood gases
Arterial and venous blood gases at FiO2 1.0, 0.5, and
0.21 at the end of EVLP are presented in Table 1. In the
HBD group, the PaO2 was 68.6 ± 2.4 kPa and in the
DCD group, the PaO2 was 51.7 ± 2.0 kPa after completed
EVLP at FiO2 1.0. (p < 0.01).
Hemodynamic data
Pulmonary artery flow and pulmonary artery pressure
The PAF at FiO2 1.0 in the HBD group was 2.5 ± 0.2 L/
min and in the DCD group 3.9 ± 0.1 L/min. (p < 0.001).
PAF at FiO2 0.5 and FiO2 0.21 were identical to PAF
values at FiO2 1.0 (Fig. 2).
The PAP at FiO2 1.0 in the HBD group was 19.8 ±
0.2 mmHg and in the DCD group 17.8 ± 1.2 mmHg
(n.s). PAP at FiO2 0.5 and FiO2 0.21 were identical to
PAP values at FiO2 1.0.
Pulmonary vascular resistance
The PVR was calculated at the different FiO2 at 1.0, 0.5,
and 0.21 and is also presented in Fig. 3. The PVR at
FiO2 1.0 was calculated to 655 ± 45 dyne x s/cm
5 in the
HBD group and in the DCD group PVR was 372 ± 31
dyne x s/cm5 (p < 0.001).
Table 1 Arterial and venous blood gases at FiO2 1.0, 0.5, and
0.21 at the end of EVLP
HBD DCD HBD-DCD
(Mean + SEM) (p-value)
PaO2 (kPa)
FiO2 1.0 68.6 ± 2.44 51.7 ± 2.05 <0. 01
FiO2 0.5 28.6 ± 1.89 23.4 ± 0.80 n.s.
FiO2 0.21 10.1 ± 0.26 9.0 ± 0.35 n.s.
PaCO2 (kPa)
FiO2 1.0 3.3 ± 0.23 3.5 ± 0.09 n.s.
FiO2 0.5 3.4 ± 0.27 3.3 ± 0.09 n.s.
FiO2 0.21 3.4 ± 0.17 3.6 ± 0.10 n.s.
PvO2 (kPa)
FiO2 1.0 6.5 ± 0.13 7.1 ± 0.14 n.s.
FiO2 0.5 6.6 ± 0.12 6.9 ± 0.20 n.s.
FiO2 0.21 3.7 ± 0.03 5.9 ± 0.40 <0. 001
PvCO2 (kPa)
FiO2 1.0 3.9 ± 0.05 3.8 ± 0.09 n.s.
FiO2 0.5 3.7 ± 0.17 3.6 ± 0.18 n.s.
FiO2 0.21 3.8 ± 0.03 4.1 ± 0.08 n.s.
FiO2 = Inspired oxygen fraction, PaO2 = arterial oxygen partial pressure,
PaCO2 = arterial carbon dioxide partial pressure, PvO2 = venous oxygen partial
pressure, PvCO2 = venous carbon dioxide partial pressure. HBD = heart-beating-
donor group, DCD = donation after cardiac death. Significance was defined as
p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) and p > 0.05 (n.s.)
Fig. 2 The mean pulmonary artery flow (PAF ± SEM) after Ex Vivo Lung
Perfusion (EVLP) is illustrated for the two groups: Heart Beating Donor
(HBD) and Donation after Cardiac Death (DCD) at different fractions of
inspired oxygen (FiO2). Significance was defined as p < 0.05 (*), p < 0.01
(**), p< 0.001 (***) and p> 0.05 (n.s.)
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Pulmonary graft compliance
After evaluation of the lungs, they were disconnected
from the ventilator and a collapse test was performed. If
the lungs do not collapse this may indicate lung injury,
lung edema, or pneumonia. All the lungs from both
study groups collapsed as they should, and showed good
compliance. No macroscopically differences between the
lungs from the two groups were seen.
Weight of lungs
The lungs were weighed after harvesting, before EVLP,
and after EVLP to assess the degree of lung edema. Be-
fore EVLP, the mean lung weight in the HBD group was
510 ± 21 g and in the DCD group 558 ± 21 g (n.s). After
EVLP, the lung weight for the HBD group was 513 ±
20 g and for the DCD group 589 ± 24 g (n.s) (Fig. 3).
Thrombotic material
After completing the lung evaluation, the pulmonary ar-
terial branches were macroscopically studied for throm-
botic material by opening the arteries as far distally as
possible. No thrombotic material was observed in any of
the groups.
Discussion
With a vast shortage of organs meeting the need for trans-
plantation, the lungs have become a center of focus in po-
tential DCD. The success of Steen and colleagues in
transplanting a human uncontrolled DCD lung has led to
a new era of DCD lung transplantation [4] even if it is still
uncommon to use uncontrolled DCD lungs in clinical
practice. Spain is an exception where the extracorporeal
circulation setting is part of their protocol in using uncon-
trolled donors. This has led to the Maastricht classifica-
tion “modified uncontrolled donors” [16].
As the lung is considered to be unique among all solid
organs not relying only on perfusion to provide oxygen
and cellular respiration, but air spaces, the hypothesis
that lung tissue may stay viable after death has been
developed. The fact that pulmonary epithelial cells have
been able to be cultured from post-mortem specimens
[17] have underlined that hypothesis and that even pul-
monary vascular epithelium might maintain functionality
for a considerable period of time. A hypothesis that epi-
thelium of the pulmonary vasculature should even be
able to produce anticoagulant factors after death cannot
be sustained by any data from the literature. The toler-
ance of warm ischemia of the lungs and the remaining
suitability of lung function has been investigated broadly.
There is today a convincing amount of experimental evi-
dence both from isolated animal lungs as well as from
animal transplantation models indicating that warm
ischemia of 60 min does not compromise DCD lung
function and its suitability for transplantation [13–15].
The preservation technique best suitable during and
after warm ischemia remains undecided. Ex vivo lung
perfusion has become an important tool in assessing
marginal lungs [4, 6–8, 10–12]. In DCD research, EVLP
has been applied while trying to find the best suitable
protocol for successful DCD lung transplantation.
While different approaches to avoiding post circulatory
thrombosis in DCD have been investigated, the most bene-
ficial preservation method is still unclear. The antegrade
flush technique is well established and currently the most
frequently used in clinical transplantation. Van de Wauwer
and colleagues reported interesting results using a retro-
grade flush technique [18, 19]. They reported significantly
lower PVR following their retrograde technique together
with histologically less micro thrombi compared to only
antegrade or non-flush techniques. Their studies were
in set-ups of 60 min of warm ischemia combined with
several hours of topical cooling or longer periods of
post-harvest cold storage [18, 19]. More studies need to
be conducted to determine whether a retrograde or a
combined flush technique is superior in preventing
thrombosis in DCD lungs.
The need for more ethically sensitive scenarios in
DCD requires refraining from using heparin as used in
standardized clinical HBD [20]. Some studies that have
injected heparin [4] after declared death and applied the
necessary chest compressions to the cadaver have led to
conflict with the dead donor rule [21]. In order to avoid
manipulating the cadaver, non-heparinized techniques or
fibrinolytic agents have become more important. In earlier
studies investigating the time frame of topical cooling no
heparin was used by Rega et al. [22, 23], corresponding
Fig. 3 The mean pulmonary vascular resistance (PVR ± SEM) after
Ex Vivo Lung Perfusion (EVLP) is illustrated for the two groups: Heart
Beating Donor (HBD) and Donation after Cardiac Death (DCD-NH) at
different fractions of inspired oxygen (FiO2). Significance was defined
as p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) and p > 0.05 (n.s.)
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best to potential clinical scenarios of Maastricht DCD
category 1 (death upon arrival) and category 2 (failed re-
suscitation). As heparin does not act on preformed fibrin
or micro thrombi, removing the potential appearance of
micro thrombi should only be possible using fibrinolytic
agents. There have been reports of successful results using
fibrinolytics on DCD [24–26].
In the present study, we compared no heparinized
DCD lungs after 60 min of warm in-situ ischemia
followed by 4 h cold storage with standard heparinized
HBD lungs. Our results demonstrate a difference in
blood gases when evaluating at FiO2 1.0 between the
standardized HBD lungs pre-treated with heparin
according to clinical protocol and the no heparinized
DCD lungs. The DCD group showed lower values on
PaO2 at FiO2 1.0 compared to the HBD group. Still, the
PaO2 values of the DCD lungs fully meet the standard
criteria for the acceptance for lung transplantation
according to international guidelines [27]. Even the
hemodynamic parameters showed equal or better results
for the DCD groups. The PAF reveals significantly
higher flow rates for the DCD group compared to the
standardized HBD group with a PAF almost twice as
high as in the HBD group. Our results for PVR were
likewise in favor for the DCD group, showing statistically
significant lower PVR values for DCD group than the
control HBD group. These results were surprising to us,
and we can only speculate that the different preservation
methods between HBD and DCD might have an altering
effect on the HBD lungs’ vasculature. We found pro-
longed time of the EVLP for HBD group compared to
the DCD group. A possible hypothesis is that the signifi-
cant higher flow rate (PAF) in the DCD lungs shortened
the warming phase in the EVLP procedure.
Inci et al. earlier reported the use of additive urokinase
in DCD to be superior over untreated DCD and HBD
[25]. The long warm ischemic period in their model
followed by topical cooling may have facilitated the for-
mation and occurrence of thrombosis in the pulmonary
vasculature leading to favorable results for the use of
urokinase. As our findings show better results on the
hemodynamics for the investigated DCD group it differs
from previous study results where even topical cooling
was applied after warm ischemia. It leaves the hypothesis
that additional or prolonged cooling might alter the
epithelium and maybe rather predispose it to formation
of thrombosis. Furthermore, our tests for lung compli-
ance post EVLP found no differences between the
investigated groups. Neither did we find differences on
the absence of macroscopic evidence for potential
thrombi. None of the lungs in our study developed pul-
monary oedema. The minimal weight gain for the DCD
group of around 30 g must be seen without any clinical
relevance.
Considering that a functional clinical model for Maas-
tricht DCD category 1 and 2 could generate an increased
number of grafts with good quality for transplantation, a
facilitated way of treating potential donor organs is
required. Retrieving organs without applying heparin will
aid in that process. Less conflicting procedures on the
donor body after declared death will alleviate manage-
ment for staff and relatives. Cardiac chest compressions
after death or even the handling of chest tubes for topic-
ally cooling the cadaver remains controversial. Accord-
ing to Swedish law the integrity of the body has to be
respected after death until a statement of positive organ
donation can be received from next of kin should no
written consent exist. Any scenario involving preparative
actions on the potential donor without informed consent
or without a deliberative process for the relatives will
evoke conflicting reactions. As this can be difficult in
uncontrolled DCD settings, it should be avoided accord-
ing to our opinion.
Increasing the donor pool due to facilitated procedures
where donors can be left untouched for 1 h can be a
promising step in meeting the present organ shortage.
However, limitations in our study due to the rather short
evaluation time of graft function and performance need
to be considered.
Conclusions
According to our results, DCD lungs can be safely used
without heparin to achieve almost equal or results than
common practice HBD lungs. Less conflicting procedures
on the donor body after declared death will alleviate man-
agement for staff and relatives. The positive outcome of
this animal study warrants evaluation of the method in a
clinical setting.
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